Related Experiment Videos
Inhibitory effect of anti-epidermal growth factor receptor antibody on a human gastric cancer
T Teramoto1, M Onda, A Tokunaga
1First Department of Surgery, Nippon Medical School, Tokyo, Japan.
Background:
Blockading the putative epidermal growth factor (EGF), transforming growth factor-alpha (TGF-alpha)/EGF receptor autocrine pathway with anti-EGF receptor monoclonal antibody (MoAb) might prevent the growth of tumor.
Methods:
The present study was designed to examine the effect of MoAb 528 on the growth of an EGF receptor which was hyperproducing human gastric cancer cells in vitro and in vivo.
Results:
Treatment with MoAb 528 inhibited the growth of cultured cells in a dose-dependent manner. Twenty micrograms of MoAb 528 given intraperitoneally after inoculation of 1 x 10(6) cells and 200 micrograms of the MoAb 528 given after inoculation of 1 x 10(7) cells to athymic mice inhibited the growth of the xenograft. Twenty micrograms of MoAb 528 from a miniosmotic pump, which releases its contents over 2 weeks, also prevented the growth of the xenograft when the treatment was started on the day after tumor inoculation. However, no inhibitory effect was observed when the treatment was started 3 weeks after inoculation. The binding capacity of 125I-EGF on the MoAb treated tumors was diminished in comparison with control tumors.
Conclusions:
The results suggest that MoAb 528 blocks the EGF or TGF-alpha/EGF receptor signal pathway, resulting in the inhibition of cancer cell growth. This MoAb 528 may therefore be an effective antitumor agent against human gastric cancer that shows expression of the EGF receptor.
Insights
Monoclonal antibody 528 effectively inhibits human gastric cancer cell growth by blocking the epidermal growth factor (EGF) receptor pathway. This antibody shows promise as an antitumor agent for EGF receptor-expressing gastric cancers.
Area of Science:
- Oncology
- Molecular Biology
- Immunotherapy
Background:
- The epidermal growth factor (EGF) receptor pathway plays a crucial role in tumor growth.
- Targeting this pathway with monoclonal antibodies (MoAb) is a potential strategy for cancer treatment.
- Autocrine signaling involving EGF and transforming growth factor-alpha (TGF-alpha) is implicated in tumor progression.
Purpose of the Study:
- To investigate the efficacy of MoAb 528 against human gastric cancer cells.
- To evaluate the anti-tumor effects of MoAb 528 in vitro and in vivo.
- To determine if MoAb 528 can block the EGF receptor signaling pathway.
Main Methods:
- In vitro studies using cultured human gastric cancer cells.
- In vivo studies using athymic mouse xenograft models.
- Administration of MoAb 528 via intraperitoneal injection and continuous infusion using miniosmotic pumps.
- Assessment of tumor growth inhibition and EGF binding capacity.
Main Results:
- MoAb 528 demonstrated dose-dependent inhibition of gastric cancer cell growth in vitro.
- Intraperitoneal administration of MoAb 528 significantly inhibited tumor xenograft growth in mice.
- Continuous infusion of MoAb 528 also prevented xenograft growth when initiated early post-inoculation.
- Treatment with MoAb 528 reduced the binding of EGF to tumors, indicating pathway blockade.
Conclusions:
- MoAb 528 effectively blocks the EGF/TGF-alpha/EGF receptor signaling pathway.
- This blockade leads to the inhibition of human gastric cancer cell growth.
- MoAb 528 represents a potential therapeutic agent for gastric cancers expressing the EGF receptor.